Graham Warren to Erlotinib Hydrochloride
This is a "connection" page, showing publications Graham Warren has written about Erlotinib Hydrochloride.
Connection Strength
0.142
-
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Sep; 80(3):497-505.
Score: 0.142
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.